[Rimonabant improves cardiometabolic risk profile in obese or overweight subjects: overview of RIO studies].

Abstract

RIO (Rimonabant In Obesity and related disorders) is a large phase 3 programme (>6600 patients) evaluating the efficacy and safety of rimonabant (5 or 20 mg/day), a CBI receptor antagonist of endocannabinoid system, in obese or overweight patients with or without comorbidities (RIO-Europe and RIO-North America), with untreated dyslipidaemia (RIO-Lipids) or with type 2 diabetes treated with metformin or sulfonylurea (RIO-Diabetes). Compared to placebo, rimonabant 20 mg/day consistently increases weight loss, reduces waist circumference, increases HDL cholesterol, lowers triglyceride levels, diminishes insulin resistance, and reduces the prevalence of metabolic syndrome. Almost half of the metabolic effects, including adiponectin increase, occur beyond weight loss, suggesting a direct peripheral effect of rimonabant.

• Authors: A J Scheen, L G Van Gaal, J P Després, X Pi-Sunyer, A Golay, C Hanotin
• Journal: Revue medicale suisse (Rev Med Suisse) Vol. 2 Issue 76 Pg. 1916-23 (Aug 23 2006) ISSN: 1660-9379 [Print] Switzerland
• Vernacular Title: Le rimonabant améliore le profit de risque cardio-métabolique chez le sujet obèse ou en surpoids: synthèse des etudes "RIO".
• PMID: 16972542 (Publication Type: Journal Article, Review)

Chemical References

• Anti-Obesity Agents
• Cannabinoid Receptor Antagonists
• Piperidines
• Pyrazoles
• Rimonabant

Topics

• Anti-Obesity Agents (therapeutic use)
• Cannabinoid Receptor Antagonists
• Humans
• Metabolic Syndrome (prevention & control)
• Obesity (drug therapy)
• Overweight (drug effects)
• Piperidines (therapeutic use)
• Pyrazoles (therapeutic use)
• Randomized Controlled Trials as Topic
• Rimonabant